|Last: || $1.290|
|Volume: || 389,731|
As Of: 2013-06-17 13:40:27 ET
*Quotes delayed by 20min.
BioSante Pharmaceuticals Inc (NASDAQ:BPAX)
BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of various products for female sexual health and oncology. It provides LibiGel, a transdermal testosterone gel that is in Phase III clinical development for the treatment of female sexual dysfunction; and male testosterone gel for the treatment of hypogonadism in men, which is licensed to Teva Pharmaceuticals USA, Inc. The company also offers various cancer vaccines, which are in Phase I and Phase II clinical trials for the treatment of melanoma, leukemia, pancreatic, breast, and prostate cancer; The Pill-Plus, which is in Phase II clinical trials is a combination of estrogens, progestogens, and androgens to prevent testosterone deficiency; and Elestrin, a food and drug administration approved product for the treatment of hot flashes associated with menopause. BioSante Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Lincolnshire, Illinois.